IL-1β, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs

Nature Immunology

Volumn 17, Issue 6, 2016, Pages 636-645

  Bal, Suzanne M ^a   Bernink, Jochem H ^a   Nagasawa, Maho ^a   Groot, Jelle ^a   Shikhagaie, Medya M ^a   Golebski, Kornel ^a   Van Drunen, Cornelis M ^a   Lutter, Rene ^a   Jonkers, Rene E ^a   Hombrink, Pleun ^b   Bruchard, Melanie ^a   Villaudy, Julien ^a   Munneke, J Marius ^a   Fokkens, Wytske ^a   Erjeflt, Jonas S ^c   Spits, Hergen ^a   Ros, Xavier Romero ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL FATE; CELL PLASTICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RHINOSINUSITIS; CONTROLLED STUDY; EOSINOPHIL; FEMALE; GENE CONTROL; GENE CONVERSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOID CELL; MOLECULAR INTERACTION; MOUSE; NEWBORN; NONHUMAN; NOSE POLYP; PRIORITY JOURNAL; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; IMMUNOLOGY; INNATE IMMUNITY; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; METABOLISM; PNEUMONIA; RHINITIS; SCID MOUSE; SINUSITIS; TH1 CELL; TH1 TH2 BALANCE; TH2 CELL;

ANIMALS; CELL DIFFERENTIATION; CELL PLASTICITY; CELLS, CULTURED; EOSINOPHILS; FEMALE; HUMANS; IMMUNITY, INNATE; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-1BETA; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MICE; MICE, SCID; NASAL POLYPS; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RHINITIS; SINUSITIS; TH1 CELLS; TH1-TH2 BALANCE; TH2 CELLS;

EID: 84964297369     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3444     Document Type: Article

References (46)

1. Barnes P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 8, 183-192 (2008).
2. Hulse K.E, Stevens W.W, Tan B.K, & Schleimer R.P. Pathogenesis of nasal polyposis. Clin. Exp. Allergy. 45, 328-346 (2015).
3. Nagarkar D.R, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J. Allergy. Clin. Immunol. 132, 593-600 (2013).
4. Reh D.D, Wang Y, Ramanathan M. Jr, & Lane A.P. Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. Am. J. Rhinol. Allergy. 24, 105-109 (2010).
5. Barnes P.J. The cytokine network in chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 41, 631-638 (2009).
6. Kearley J, et al. Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity. 42, 566-579 (2015).
7. Holtzman M.J, Byers D.E, Alexander-Brett J, & Wang X. The role of airway epithelial cells and innate immune cells in chronic respiratory disease. Nat. Rev. Immunol. 14, 686-698 (2014).
8. McKenzie A.N, Spits H, & Eberl G. Innate lymphoid cells in inflammation and immunity. Immunity. 41, 366-374 (2014).
9. Artis D, & Spits H. The biology of innate lymphoid cells. Nature. 517, 293-301 (2015).
10. Buonocore S, et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature. 464, 1371-1375 (2010).
11. Klose C.S, et al. A T-bet gradient controls the fate and function of CCR6-RORγt+ innate lymphoid cells. Nature. 494, 261-265 (2013).
12. Bernink J.H, et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat. Immunol. 14, 221-229 (2013).
13. Bartemes K.R, Kephart G.M, Fox S.J, & Kita H. Enhanced innate type 2 immune response in peripheral blood from patients with asthma. J Allergy Clin Immunol. 134, 671-678 (2014).
14. Nagakumar P, et al. Type 2 innate lymphoid cells in induced sputum from children with severe asthma. J. Allergy Clin. Immunol. 137, 624-626.e6 (2015).
15. Mjösberg J.M, et al. Human IL-25- And IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat. Immunol. 12, 1055-1062 (2011).
16. Salimi M, et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J. Exp. Med. 210, 2939-2950 (2013).
17. Teunissen M.B, et al. Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR+ ILC3 in lesional skin and blood of psoriasis patients. J. Invest. Dermatol. 134, 2351-2360 (2014).
18. Kim H.Y, et al. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-Associated airway hyperreactivity. Nat. Med. 20, 54-61 (2014).
19. Gasteiger G, Fan X, Dikiy S, Lee S.Y, & Rudensky A.Y. Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs. Science. 350, 981-985 (2015).
20. Bernink J.H, et al. Interleukin-12 and -23 control plasticity of CD127+ group 1 and group 3 innate lymphoid cells in the intestinal lamina propria. Immunity. 43, 146-160 (2015).
21. Vonarbourg C, et al. Regulated expression of nuclear receptor RORγt confers distinct functional fates to NK cell receptor-expressing RORγt+ innate lymphocytes. Immunity. 33, 736-751 (2010).
22. Hazenberg M.D, & Spits H. Human innate lymphoid cells. Blood. 124, 700-709 (2014).
23. Roediger B, & Weninger W. Group 2 innate lymphoid cells in the regulation of immune responses. Adv. Immunol. 125, 111-154 (2015).
24. Brestoff J.R, et al. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature. 519, 242-246 (2015).
25. Mjösberg J, et al. The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity. 37, 649-659 (2012).
26. Gimeno R, et al. Monitoring the effect of gene silencing by RNA interference in human CD34+ cells injected into newborn RAG2-/- γc-/- mice: functional inactivation of p53 in developing T cells. Blood. 104, 3886-3893 (2004).
27. Hughes T, et al. Interleukin-1β selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. Immunity. 32, 803-814 (2010).
28. Cella M, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 457, 722-725 (2009).
29. Hackett T.L, Shaheen F, Zhou S, Wright J.L, & Churg A. Fibroblast signal transducer and activator of transcription 4 drives cigarette smoke-induced airway fibrosis. Am. J. Respir. Cell Mol. Biol. 51, 830-839 (2014).
30. Neurath M.F, Finotto S, & Glimcher L.H. The role of Th1/Th2 polarization in mucosal immunity. Nat. Med. 8, 567-573 (2002).
31. Miljkovic D, et al. Association between group 2 innate lymphoid cells enrichment, nasal polyps and allergy in chronic rhinosinusitis. Allergy. 69, 1154-1161 (2014).
32. Voehringer D, Shinkai K, & Locksley R.M. Type 2 immunity reflects orchestrated recruitment of cells committed to IL-4 production. Immunity. 20, 267-277 (2004).
33. Sojka D.K, et al. Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells. eLife. 3, e01659 (2014).
34. Silver J.S, et al. Inflammatory triggers associated with COPD exacerbations orchestrate ILC2 plasticity in the lung. Nat. Immunol. doi:10.1038/ni.3443 (2016).
35. Barnes P.J. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. J. Allergy Clin. Immunol. 136, 531-545 (2015).
36. Molofsky A.B, et al. Interleukin-33 and interferon-γ counter-regulate group 2 innate lymphoid cell activation during immune perturbation. Immunity. 43, 161-174 (2015).
37. Nussbaum J.C, et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature. 502, 245-248 (2013).
38. Southworth T, et al. IFN-γ synergistically enhances LPS signalling in alveolar macrophages from COPD patients and controls by corticosteroid-resistant STAT1 activation. Br. J. Pharmacol. 166, 2070-2083 (2012).
39. Lee B.J, et al. Protective effects of basic fibroblast growth factor in the development of emphysema induced by interferon-γ. Exp. Mol. Med. 43, 169-178 (2011).
40. Bachert C, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. J. Am. Med. Assoc. 315, 469-479 (2016).
41. Wenzel S, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med. 368, 2455-2466 (2013).
42. Beck L.A, et al. Dupilumab treatment in adults with moderate-To-severe atopic dermatitis. N. Engl. J. Med. 371, 130-139 (2014).
43. Gevaert P, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J. Allergy Clin. Immunol. 118, 1133-1141 (2006).
44. Gevaert P, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J. Allergy Clin. Immunol. 128, 989-995 (2011).
45. Corren J, et al. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365, 1088-1098 (2011).
46. Abt M.C, et al. innate immune defenses mediated by two ILC subsets are critical for protection against acute Clostridium difficile infection. Cell Host Microbe. 18, 27-37 (2015).